DGCI allows Serum Institute to export malaria vaccine to U.K.

The Drugs Controller General of India (DCGI) has granted permission to send two lakh doses of the vaccine

September 29, 2022 06:08 pm | Updated 06:08 pm IST - New Delhi

File photo of a nurse filling a syringe with malaria vaccine for representation.

File photo of a nurse filling a syringe with malaria vaccine for representation. | Photo Credit: Reuters

India's drug regulator has allowed the export of the first produced-in-India vaccine against malaria, developed by scientists at the University of Oxford and manufactured by Serum Institute to the U.K., official sources said on Thursday.

The Drugs Controller General of India (DCGI) has granted permission to send two lakh doses of the vaccine.

The move comes after an application was submitted by Prakash Kumar Singh, director, Government and Regulatory Affairs, at Serum Institute of India (SII) to DCGI on September 27 seeking permission to export the vaccine against malaria, official sources told PTI.

"SII has developed the vaccine against malaria under leadership of our CEO Dr Adar C Poonawalla. We have been relentlessly working to make available made-in-India and world-class vaccines against malaria to our country and world at large," an official source quoted Singh as having said in the application.

Currently, only one vaccine against malaria is available globally and GSK is the manufacturer of that.

The malaria vaccine was designed at the Jenner Institute, University of Oxford, which collaborated with the SII in 2020 to manufacture and develop the jab for large- scale supply, the sources said.

The vaccine trial results which included 409 children in Nanoro, Burkina Faso showed that three initial doses followed by a booster after a year gives up to 80 per cent protection against the disease, they said.

The SII along with Oxford University is currently doing advanced-stage trials in African countries.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.